Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose cytarabine followed by blinatumomab for relapsed/refractory childhood CD19-positive B-cell precursor acute lymphoblastic leukemia
jRCTs041210107Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab and cytarabine in acute lymphoblastic leukemia (ALL) and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Hematological complete remission rate after second cycle of blinatumomab. Started Jan 2022; status: active, not recruiting.
02
Drugs
blinatumomabcytarabine
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on jRCTs041210107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210107.